Publications

  • Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA,Odero MD. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica. 2015 Jan 30. pii: haematol.2014.118117. PubMed PMID: 25637054. Impact Factor: 6.532. Ranking: 7/65 (HEMATOLOGY).

    ABSTRACT CORTESÍA DE PUBMED

  • Cortés-Lavaud X, Landecho MF, Maicas M, Urquiza L, Merino J, Moreno-Miralles I, Odero MDGATA2 Germline Mutations Impair GATA2 Transcription, Causing Haploinsufficiency: Functional Analysis of the p.Arg396Gln Mutation. J Immunol. 2015 Mar 1;194(5):2190-8. doi: 10.4049/jimmunol.1401868. Epub 2015 Jan 26. PubMed PMID: 25624456. Impact Factor: 5.362. Ranking: 24/144 (IMMUNOLOGY).

    ABSTRACT CORTESÍA DE PUBMED

  • Laguna T, Notario L, Pippa R, Fontela MG, Vázquez BN, Maicas M, Aguilera-Montilla N, Corbí ÁL, Odero MD, Lauzurica P. New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence. Mol Immunol. 2015 Mar 19;66(2):171-179. doi: 10.1016/j.molimm.2015.02.031. PubMed PMID: 25801305. Impact Factor: 3.003. Ranking: 66/144 (IMMUNOLOGY).

ABSTRACT CORTESÍA DE PUBMED

  • Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD (2014) Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia. SET binding drugs have antagonistic activity. Leukemia. 2014 Sep;28(9):1915-8. doi: 10.1038/leu.2014.141. Epub 2014 Apr 30. PMID: 24781014. Impact Factor: 10.164. Ranking: 4/65 (HEMATOLOGY). Sustituir esta por la primera que está ahora, que ya no está paginada

ABSTRACT CORTESÍA DE PUBMED

  • Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Blanco-Prieto MJ, Odero MD. (2014) Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. Journal of Biomedical Nanotechnology. Journal of Biomedical Nanotechnology. 2015 (11) 691-701. Impact Factor: 5.256. Ranking: 17/69 (Nanoscience & Nanotechnology).

ABSTRACT CORTESÍA DE PUBMED

  • Anupriya A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen D, Druker BJ (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia. Clin Cancer Res. 2014 Apr 15;20(8):2092-103. doi: 10.1158/1078-0432.CCR-13-2575. Epub 2014 Jan 16. PMID: 24436473. Impact Factor: 7.837. Ranking: 12/196 (ONCOLOGY).

ABSTRACT CORTESÍA DE PUBMED

  • Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia. SET binding drugs have antagonistic activity. Leukemia. 2014 Apr 30. doi: 10.1038/leu.2014.141. [Epub ahead of print] PubMed PMID: 24781014. Impact Factor 2010: 10.164. Ranking: 4/65 (HEMATOLOGY)
    ABSTRACT CORTESÍA DE PUBMED

  • Agarwal A, Mackenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clin Cancer Res. 2014 Apr 15;20(8):2092-103. doi: 10.1158/1078-0432.CCR-13-2575. Epub 2014 Jan 16. PubMed PMID: 24436473; PubMed Central PMCID: PMC3989420. Impact Factor 2012: 7.837. Ranking: 12/196 (ONCOLOGY)
    ABSTRACT CORTESÍA DE PUBMED

  • Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol. 2014 Jan 9;7(1):4. doi: 10.1186/1756-8722-7-4. PubMed PMID: 24405639; PubMed Central PMCID: PMC3900738.
    ABSTRACT CORTESÍA DE PUBMED

  • Maicas M, Vázquez I, Vicente C, Garcia-Sanchez MA, Marcotegui N, Urquiza L, Calasanz MJ, Odero MD (2013) Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. Oncogene 32(16):2069-78 (PMID: 22689058). Epub 2012 Jun 11. Impact Factor 2010: 7.414. Ranking: 15/185 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cristobal I, Cirauqui C, Castelló-Cros R, Garcia-Orti L, Calasanz MJ, Odero MD (2013) Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica Jun 28. [Epub ahead of print]. Impact Factor 2010: 6.532. Ranking: 7/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Mollinedo F, Odero MD, Blanco-Príeto MJ. (2013) Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett 334:302-10. (PMID: 23353057) Epub 2013 Jan 23. Impact Factor 2011: 4.238. Ranking: 43/196 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Garcia-Orti L, Cristobal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ, Castello-Cros R, Odero MD (2012). Integration of SNP and mRNA Arrays with MicroRNA Profiling Reveals that MiR-370 is Upregulated and Targets NF1 in Acute Myeloid Leukemia. PLoS ONE 7(10): e47717. doi:10.1371/journal.pone.0047717. Impact Factor 2011: 4.092. Ranking: 12/86 (BIOLOGY)
    ABSTRACT CORTESÍA DE PUBMED

  • Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ, Odero MD (2012) Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97:543-50 (PMID: 22133779). Impact Factor 2010: 6.532. Ranking: 7/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J (2012). Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia with Normal Cytogenetics. (PMID:22912701) PLoS One. 2012;7:e42334. Epub 2012 Aug 9. Impact Factor 2011: 4.092. Ranking: 12/86 (BIOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, González M, Calasanz MJ, Lahortiga I, Odero MD (2011) Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia (PMID: 21904383) 26:550-4. Impact Factor 2010: 8.966. Ranking: 4/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Agirre X, Martínez-Climent JA, Odero MD, Prosper F (2011) Epigenetic regulation of miRNA genes in Acute Leukemia. Leukemia. 26:395-403 (PMID: 22143672). Impact Factor 2010: 8.966. Ranking: 4/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Gomez-Benito M, Loayza-Puch F, Oude Vrielink J, Odero MD, Agami R (2011). 3'UTR-Mediated Gene Silencing of the Mixed Lineage Leukemia (MLL) Gene. PLoS One. 2011; 6:e25449. (PMID: 21998658). Epub 2011 Oct 5. Impact Factor 2010: 4.411. Ranking: 12/86 (BIOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain AL, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C (2011). Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One (PMID: 22069467) 2011; 6:e26740. Epub 2011 Nov 1. Impact Factor 2010: 4.411. Ranking: 12/86 (BIOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gomez-Casares MT, Hernandez-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD (2011) Downregulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica (PMID: 21750091). 2011; 96:1448-56. Impact Factor 2010: 6.532. Ranking: 7/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vicente C, Conchillo A, García-Sánchez MA, Odero MD (2011) The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Critical Reviews in Oncology/Hematology (PMID: 21605981) 82:1-17. Impact Factor 2010: 4.689. Ranking: 14/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cristóbal I, Garcia-Orti L, Cirauqui C, Calasanz MJ, Alonso MM, Odero MD (2011). PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent antileukemic effect. Leukemia (PMID: 21233840) 25: 606-614. Impact Factor 2010: 8.966. Ranking: 4/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O, Gerbino V, Egurbide I, Odero MD, Bertolini F, Pelicci PG (2011). In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia (PMID: 21252985) 25:733-736. Impact Factor 2010: 8.966. Ranking: 4/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K, Mestdagh P, Van Maerken T, Van Roy N, Jeison M, Yaniv I, Cauwelier B, Noens L, Poirel HA, Vandenberghe P, Lambert F, De Paepe A, Sánchez MG, Odero M, Verhasselt B, Philippé J, Vandesompele J, Wieser R, Dastugue N, Van Vlierberghe P, Poppe B, Speleman F. (2011) EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol (PMID: 21569010) 154:337-348. Impact Factor 2010: 4.942. Ranking: 11/65 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, Novo FJ, Bandres E, Calasanz MJ, Bernabeu C, Odero MD (2010). SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood (PMID: 19965692), 115(3):615-625. Impact Factor 2009: 10.555. Ranking: 2/61 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Gómez-Benito M, Conchillo A, García MA, Vázquez I, Maicas M, Vicente C, Cristóbal I, Marcotegui N, Garcia-Orti L, Bandrés E, Calasanz MJ, Alonso MM, Odero MD (2010). EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. British Journal of Cancer (PMID: 20842122), 103:1292-6. Impact Factor 2009: 4.346. Ranking: 35/166 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vázquez I, Maicas M, Marcotegui N, Conchillo A, Guruceaga E, Roman-Gomez J, Calasanz MJ, Agirre A, Prosper F, Odero MD (2010). Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America (PNAS) (PMID: 20930122), 107:E167-8. Impact Factor 2009: 9.432. Ranking: 3/50 (Multidisciplinary Sciences)
    ABSTRACT CORTESÍA DE PUBMED

  • De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J. (2008). In vitro validation of gamma-secretase inhibitors alone or in combination with other drugs for treatment of T-cell acute lymphoblastic leukemia. Haematologica (PMID: 18322257), 93:533-42. Impact Factor 2008: 5.978. Ranking: 9/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B, Lahortiga I, Odero MD, Gruszka A, Minucci S, Di Fiore PP and Pelicci PG (2007) sPRDM16 and p53-loss cooperate in expanding hematopoietic stem and progenitor cells and inducing myeloid leukemias. Journal of Clinical Investigation (PMID: 18037989), 117: 3696–3707. Impact Factor 2007: 16.915. Ranking: 2/81 (MEDICINE, RESEARCH & EXPERIMENTAL)
    ABSTRACT CORTESÍA DE PUBMED

  • Vicente C, Vázquez I, Marcotegui N, Rivell G, Bandrés E, Larrayoz MJ, Lahortiga I, Calasanz MJ, Odero MD (2007) JAK2-V617F activating mutation in acute myeloid leucemia: prognostic impact and association with other molecular markers. Leukemia (PMID: 17581610), 21: 2386-2390. Impact Factor 2007: 6.924. Ranking: 6/63 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo B, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink J, Cools J. (2007) Duplication of the MYB oncogene in T-cell acute lymphoblastic leukemia. Nature Genetics (PMID: 17435759), 39:593-595. Impact Factor 2007: 25.556. Ranking: 1/132 (GENETICS).
    ABSTRACT CORTESÍA DE PUBMED

  • Suela J, Alvarez S, Cifuentes F, Largo C, Ferreira B, Blesa D, Ardanaz MT, Garcia R, Marquez J, Odero MD, Calasanz MJ, Cigudosa JC. (2007) DNA profiling análisis of 100 consecutive de novo acute myeloid leucemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia (PMID: 17377590), 21:1224-1231. Impact Factor 2007: 6.924. Ranking: 6/63 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lahortiga I, Vazquez I, Belloni E, Roman JP, Gasparini P, Novo FJ, Zudaire I, Pelicci PG, Hernandez JM, Calasanz MJ, Odero MD (2005) FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome. Hum Genet (PMID: 15744521) 116:476-485. Impact Factor 2005: 4.331. Ranking: 24/124 (GENETICS).
    ABSTRACT CORTESÍA DE PUBMED

  • Odero MD, Grand FH, Iqbal S, Ross F, Roman JP, Vizmanos JL, Andrieux J, Lai JL, Calasanz MJ, Cross NC (2005) Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia (PMID: 15618963) 19:245-252. Impact Factor 2005: 6.612. Ranking: 13/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J (2005) Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood (PMID: 15713800) 105:4849-4852. Impact Factor 2005: 10.131. Ranking: 2/60 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Valganon M, Giraldo P, Agirre X, Larrayoz MJ, Rubio-Martinez A, Rubio-Felix D, Calasanz MJ, Odero MD (2005) p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol (PMID: 15801955) 129:53-59. Impact Factor 2005: 4.080. Ranking: 13/60 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Martin-Subero JI, Odero MD, Hernandez R, Cigudosa JC, Agirre X, Saez B, Sanz-Garcia E, Ardanaz MT, Novo FJ, Gascoyne RD, Calasanz MJ, Siebert R (2005) Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer (PMID: 15852472) 43:414-423. Impact Factor 2005: 3.937. Ranking: 35/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lahortiga I, Agirre X, Belloni E, Vazquez I, Larrayoz MJ, Gasparini P, Lo Coco F, Pelicci PG, Calasanz MJ, Odero MD (2004) Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene (PMID: 14712237) 23:311-316. Impact Factor 2004: 6.318. Ranking: 11/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lahortiga I, Vazquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A, Calasanz MJ, Odero MD (2004) Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer (PMID: 15138998) 40:179-189. Impact Factor 2004: 4.276. Ranking: 27/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vazquez I, Lahortiga I, Agirre X, Larrayoz MJ, Vizmanos JL, Ardanaz MT, Zeleznik-Le NJ, Calasanz MJ, Odero MD (2004) Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2. Leukemia (PMID: 15483676) 18:2041-2044. Impact Factor 2004: 5.810. Ranking: 5/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Pio R, Zudaire I, Pino I, Castano Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, Calasanz MJ, Montuenga LM (2004) Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res (PMID: 15205328) 64:4171-4179. Impact Factor 2004: 7.690. Ranking: 9/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Saez B, Martin-Subero JI, Guillen-Grima F, Odero MD, Prosper F, Cigudosa JC, Harder L, Calasanz MJ, Siebert R (2004) Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes. Leukemia (PMID: 14712294) 18:654-657. Impact Factor 2004: 5.810. Ranking: 5/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC (2004) NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res (PMID: 15087377) 64:2673-2676. Impact Factor 2004: 7.690. Ranking: 9/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Lahortiga I, Vizmanos JL, Agirre X, Vazquez I, Cigudosa JC, Larrayoz MJ, Sala F, Gorosquieta A, Perez-Equiza K, Calasanz MJ, Odero MD (2003) NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15). Cancer Res (PMID: 12810632) 63:3079-3083. Impact Factor 2003: 8.649. Ranking: 7/120 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Chinwalla V, Chien A, Odero MD, Neilly MB, Zeleznik-Le NJ, Rowley JD (2003) A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15. Oncogene (PMID: 12618766) 22:1400-1410. Impact Factor 2003: 6.495. Ranking: 24/156 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cigudosa JC, Odero MD, Calasanz MJ, Sole F, Salido M, Arranz E, Martinez-Ramirez A, Urioste M, Alvarez S, Cervera JV, MacGrogan D, Sanz MA, Nimer SD, Benitez J (2003) De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. Genes Chromosomes Cancer (PMID: 12619165) 36:406-412. Impact Factor 2003: 4.192. Ranking: 25/120 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Garcia JL, Hernandez JM, Gutierrez NC, Flores T, Gonzalez D, Calasanz MJ, Martinez-Climent JA, Piris MA, Lopez-Capitan C, Gonzalez MB, Odero MD, San Miguel JF (2003) Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia (PMID: 14513052) 17:2016-202. Impact Factor 2003: 5.116. Ranking: 15/123 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Odero MD, Vizmanos JL, Roman JP, Lahortiga I, Panizo C, Calasanz MJ, Zeleznik-Le NJ, Rowley JD, Novo FJ (2002) A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer (PMID: 12203785) 35:11-19. Impact Factor 2002: 4.199. Ranking: 23/120 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, Hagemeijer A, Marynen P (2002) Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood (PMID: 11861295) 99:1776-1784. Impact Factor 2002: 9.631. Ranking: 2/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD (2001) Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer (PMID: 11319801) 31:134-142. Impact Factor 2001: 4.416. Ranking: 23/120 (ONCOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Odero MD, Carlson KM, Calasanz MJ, Rowley JD (2001) Further characterization of complex chromosomal rearrangements in myeloid malignancies: spectral karyotyping adds precision in defining abnormalities associated with poor prognosis. Leukemia (PMID: 11455985) 15:1133-1136. Impact Factor 2001: 4.293. Ranking: 7/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Odero MD, Matutes E, Valganon M, Cigudosa JC, Bengoechea E, Calasanz MJ (2001) Complex karyotype in one patient with small cell variant of T-prolymphocytic leukemia. Analysis by G-banding and comparative genomic hybridization. Haematologica (PMID: 11255284) 86:324-325. Impact Factor 2001: 3.216. Ranking: 13/62 (HEMATOLOGY).
    ABSTRACT CORTESÍA DE PUBMED

  • Cortés-Lavaud X, Landecho MF, Maicas M, Urquiza L, Merino J, Moreno-Miralles I, Odero MD. GATA2 Germline Mutations Impair GATA2 Transcription, Causing Haploinsufficiency: Functional Analysis of the p.Arg396Gln Mutation. J Immunol. 2015 Mar 1;194(5):2190-8. doi: 10.4049/jimmunol.1401868. Epub 2015 Jan 26. PubMed PMID: 25624456. 
    ABSTRACT CORTESÍA DE PUBMED

  • Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica. 2015 Jan 30. pii: haematol.2014.118117. [Epub ahead of print] PubMed PMID: 25637054. 
    ABSTRACT CORTESÍA DE PUBMED

  • Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD*, Blanco-Prieto MJ*. (2014) Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. Journal of Biomedical Nanotechnology. Journal of Biomedical Nanotechnology. 2015 (11) 691-701. 

  • Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen D, Druker BJ (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia. Clin Cancer Res. 2014 Apr 15;20(8):2092-103. doi: 10.1158/1078-0432.CCR-13-2575. Epub 2014 Jan 16. PMID: 24436473. 
    ABSTRACT CORTESÍA DE PUBMED

 

 

 

 



"Despite advances in acute myeloid leukemia, the percentage of patients who relapse is very high. Studies are therefore needed that open new therapeutic perspectives aimed at molecular targets. Our laboratory is working on the discovery and characterization of small molecules that activate the tumor-suppressing protein PP2A for the treatment of this leukemia" , Dra. María D. Odero, Principal Investigator..

More information:

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es